Liana Moussados

Wedbush believes Sangamo BioSciences, Inc. (NASDAQ: SGMO) lacks any upside potential until the year 2018, citing the pipeline gap in the face of the management’s overhauling efforts. Therefore, the firm thinks it proper to downgrade the stock from an Outperform to a Neutral rating and slashed...